|
|
|
| Clinical effect of Tansoloxin and Levofloxacin in the treatment of chronic prostatitis |
| LI Yuebing XING Jialong ZONG Zhaohui ZHANG Huajun |
| Department of Urology, Rugao People’s Hospital, Jiangsu Province, Rugao 226500, China |
|
|
|
Abstract Objective To analyze the clinical effect of Tansoloxin and Levofloxacin in the treatment of chronic prostatitis. Methods From April 2017 to May 2020, 86 patients with chronic prostatitis were divided into control group and observation group according to the treatment plan, with 43 cases in each group. The control group was treated with Levofloxacin, the observation group was treated with Tansororosin and Levofloxacin. The clinical effect of two groups after treatment was analyzed. Results After three weeks of treatment, the total effective rate in the observation group was higher than that in the control group (P ＜ 0.05). There were no significant differences in interleukin (IL)-2, IL-6, macrophage inflammatory protein-2 (MIP-2), macrophage inflammatory protein-1α (MIP-1), leukocyte and lecithin corpuscles between the two groups before treatment (P ＞ 0.05). After three weeks of treatment the lecithin bodies in prostate fluid in the two groups increased, IL-2, IL-6, MIP-2, MIP-1α and white blood cells decreased compared with those before treatment, and the lecithin bodies in prostate fluid in the observation group were higher than those in the control group, and the inflammatory factors and white blood cells were lower than those in the control group (P ＜ 0.05). There was no significant difference in national institutes of health chronic prostatitis index (NIH-CPSI) score between the two groups before treatment (P ＞ 0.05). The pain, voiding symptoms, quality of life and total score of NIH-CPSI in the two groups decreased compared with before treatment, and those in the observation group were lower than the control group (P ＜ 0.05). Conclusion Tansoloxin combined with Levofloxacin in the treatment of chronic prostatitis can reduce inflammation, improve symptoms and improve the curative effect.
|
|
|
|
|
|
1] 杨林，熊波，罗军，等.慢性前列腺炎对男性不育患者精液的影响及机制研究[J].重庆医学，2019，48（14）：2487-2489.
[2] 赵俊峰，潘世杰，杨旭凯，等.高龄前列腺炎患者临床特点[J].中国老年学杂志，2018，38（23）：5762-5764.
[3] 俞王海，詹建飞，宋立德.高压氧联合坦索罗辛和左氧氟沙星治疗Ⅲ型前列腺炎患者60例疗效观察[J].中华航海医学与高气压医学杂志，2019，26（3）：241-243.
[4] 应俊辉，周长春，金亿里，等.左氧氟沙星联合中药治疗慢性前列腺炎的疗效及对患者免疫功能的影响[J].中国临床保健杂志，2019，22（3）：356-358.
[5] Dewitt-Foy ME，Nickel JC，Shoskes DA. Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome[J]. Eur Urol Focus，2019，5（1）：2.
[6] 那彦群，叶章群，孙光.中国泌尿外科疾病诊断治疗指南[S].北京：人民卫生出版社，2011：132-146.
[7] 黄鹏.经尿道前列腺等离子电切术治疗前列腺增生合并前列腺炎对患者性功能及生活质量的影响[J].医学临床研究，2018，2（2）：362-364.
[8] 李萍，潘伯臣，谭书韬.慢性细菌性与非细菌性前列腺炎对男性精液质量及精子功能的影响[J].中国医科大学学报，2020，49（4）：354-356.
[9] Herasca?觡as V，Gutiérrezsoto B，Almontefernández H，et al. Antibiotic activity and concentrations in clinical samples from patients with chronic bacterial prostatitis[J]. Actas Urol Esp，2017，41（10）：112-115.
[10] 张洁，冯传顺，廖苏才.多沙唑嗪联合帕罗西汀治疗非细菌性慢性前列腺炎的疗效[J].安徽医学，2020，41（1）：9-12.
[11] 陈膺仲，宫小勇，雷毅，等.前列化浊丸联合左氧氟沙星治疗ⅢA型前列腺炎疗效观察[J].河北医学，2017，23（12）：2083-2087.
[12] 符仕宝，何书明，肖劲逐，等.结石康胶囊联合盐酸坦洛新缓释胶囊治疗慢性前列腺炎合并前列腺结石临床观察[J].中华中医药学刊，2020，38（5）：228-231.
[13] Ferré LC，Llopis RF，Jacob RJ，et al. Factors associated with emergency department revisits for acute bacterial prostatitis [J]. Emergencias，2017，29（2）：105.
[14] 许盛飞，库尔班江·阿布力克木，曹鹏，等.慢性前列腺炎/慢性盆腔疼痛综合征病人的尿动力学特点及其临床意义[J].临床外科杂志，2020，28（3）：270-272.
[15] Cai T，Verze P，Rocca RL，et al. The Clinical Efficacy of Pollen Extract and Vitamins on Chronic Prostatitis/Chronic Pelvic Pain Syndrome Is Linked to a Decrease in the Pro-Inflammatory Cytokine Interleukin-8[J]. World J Mens Health，2017，35（2）：120-128.
[16] 宋勇波，刘玉.坦索罗辛与索利那新联合治疗Ⅲ型前列腺炎临床效果观察[J].实用医院临床杂志，2018，15（4）：252-254.
[17] 马燕，朱文通，陈惠峰.左氧氟沙星联合利福喷丁治疗对复治涂阳肺结核患者临床疗效及不良反应发生的影响[J].临床和实验医学杂志，2020，19（24）：2640-2643.
[18] 李泰标，张芸，谢洪武.热敏灸联合盐酸坦索罗辛缓释胶囊治疗慢性前列腺炎临床观察及对血液流变影响[J].中华中医药杂志，2018，33（12）：5694-5696.
[19] 姚泽钦，陈国强，汪溢，等.左氧氟沙星联合坦索罗辛治疗慢性前列腺炎的临床效果[J].中国医药，2020，15（8）：1276-1279.
[20] 唐硕，李云祥.观察盐酸坦索罗辛与抗感染药物结合治疗慢性前列腺炎的疗效[J].中国性科学，2018，27（8）：25-28.
[21] Fo SG，Oliveira AC，Ribeiro EL，et al. Intraurethral injection with LPS： an effective experimental model of prostatic inflamm [J]. Inflamm Res，2018，67（1）：43-55.
[22] Murphy SF，Schaeffer AJ，Done JD，et al. Commensal bacterial modulation of the host immune response to ameliorate pain in a murine model of chronic prostatitis [J]. Pain，2017，158（8）：1517-1527.
[23] 杨洁泉，崔猛胜，白骏恒，等.血清PCT、CRP与IL-6对乳腺癌手术后切口感染检测的诊断意义[J].中国现代医生，2019，57（10）：5-8.
[24] 黄健，邓宏伟，陈丹，等.普适泰与地奥司明对老年慢性前列腺炎患者血清和前列腺液中MMP-2和MIP-1α的影响[J].现代生物医学进展，2017，17（25）：4920-4923.
[25] 崔崎，韩玲，成俊，等.前列腺液中免疫球蛋白、细胞因子及趋化因子水平与慢性前列腺炎的关系[J].现代免疫学，2017（5）：412-416.
[26] 鲁鹏，蒋迎春.利湿通淋中药联合左氧氟沙星治疗慢性前列腺炎疗效及对白细胞计数、卵磷脂小体水平的影响[J].现代中西医结合杂志，2018，27（3）：281-284.
[27] 何涛，黄华武，曾永龙，等.固有免疫分子NLRP3炎性小体在慢性细菌性前列腺炎中的作用[J].中国医药导报，2019，16（10）：157-161. |
|
|
|
